CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Most Recent Articles

Providence Saint John’s Health Center was one of three Providence hospitals in the Southland to have been designated as a Blue Distinction Center for Cardiac Care.

Providence Alaska has named Sarah Skeel as Chief Administrative Officer of Providence Alaska Medical Center, beginning Feb. 12.

Providence St. Joseph Hospital in Eureka is pleased to announce that Healthgrades, the leading marketplace connecting doctors and patients, has awarded the hospital with a top 5 hospital ranking in Ca

The Commission on Cancer, a quality program of the American College of Surgeons, has awarded a three-year accreditation to the cancer program at Providence Alaska Medical Center.

Finding the right kind of care – at the right time and place – shouldn’t be difficult. We detail your options so you can easily determine which is best for YOU.

Finding the right kind of care – at the right time and place – shouldn’t be difficult. we detail your options so you can easily determine which is best for YOU.

Providence Alaska and Anchorage re:MADE have partnered to repurpose used surgical wrap and help reduce the amount of hospital waste. The material is turned into tote bags and paint drop cloths.

As of April 27, 2023, Providence Mission Hospital will relocate its outpatient physical therapy clinic from Forbes Road to the hospital’s Mission Viejo campus, which is less than two miles away.

Using MRI-guided radiation, Providence radiation oncologists can precisely target tumors for destruction while minimizing damage to surrounding normal tissue.

Providence Saint John’s Health Center is now equipped to offer Aquablation therapy, a state-of-the-art robotic procedure to treat men with enlarged prostates.

ION Robot Offers Hope for Lung Cancer Patients. Brothers receive lifesaving diagnoses with advanced-tech tool.

Innovations that empower the human connection top the list of Providence’s fifth-annual health care predictions.

On Jan. 20, 2023, the congressman met with Providence caregivers at the site of the future housing project to celebrate and award the funding.

The scholarship— made possible by Queen of the Valley Foundation and Napa Valley Community Foundation—began accepting applications this month

Providence caregivers give immunocompromised patients a chance of normalcy during the pandemic.

One patient tells his inspiring story of recovery

For third year in a row, Providence St. Vincent Medical Center has received America’s 50 Best Hospitals Award. This recognition places Providence among the top 1% of the country's hospital